Genascence

About:

Clinical-stage biotechnology company developing life-changing gene therapy products for musculoskeletal diseases

Top Investors: Pacira Pharmaceuticals, DeepWork Capital, California Institute for Regenerative Medicine, University of Florida Research Foundation, Polymerase Capital

Description:

Genascence is a clinical-stage biotechnology company that is using gene therapy to revolutionize the treatment of common musculoskeletal diseases. The company intends to tackle one of the most serious problems in medicine: osteoarthritis, which is the leading cause of disability, chronic pain, and a significant risk factor for opioid addiction (OA).

Total Funding Amount:

$27.1M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Palo Alto, California, United States

Founded Date:

2017-01-01

Founders:

Thomas W. Chalberg, PhD

Number of Employees:

1-10

Last Funding Date:

2023-02-23

IPO Status:

Private

Industries: